A Phase 2 Study of Enasidenib in People With T-Cell Lymphoma

Full Title

Purpose

Researchers want to see how well the drug enasidenib works in people with angioimmunoblastic T-cell lymphoma (AITL). The people in this study have AITL that came back or keeps growing after treatment. Their cancers also have a mutation (change) in the IDH2 gene.

Enasidenib blocks the mutated IDH2 protein. This blocking action may improve your blood cell counts and stop or slow the growth of cancer cells. Enasidenib is taken orally (by mouth).

People who also have B-cell lymphoproliferation will get rituximab with enasidenib. With B-cell lymphoproliferation, there is uncontrolled growth of white blood cells called lymphocytes in the blood or lymph nodes. Rituximab is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have AITL that came back or keeps growing after treatment and has an IDH2 mutation.
• Have finished prior lymphoma therapies at least 2 weeks before getting the study therapy.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Zachary Epstein-Peterson’s office at 646-608-4176.